149057-19-2

Basic information

• Product Name: N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID
• Synonyms: PIPERAZINE-1,2,4-TRICARBOXYLIC ACID 4-BENZYL ESTER 1-TERT-BUTYL ESTER;PIPERAZINE-2-CARBOXYLIC ACID, N1-BOC PROTECTED, N4-CBZ PROTECTED;N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID;1-BOC-4-CBZ-PIPERAZINE-2-CARBOXYLIC ACID;4-[(BENZYLOXY)CARBONYL]-1-(TERT-BUTOXYCARBONYL)PIPERAZINE-2-CARBOXYLIC ACID;REF DUPL: N-1-Boc-N-4-Cbz-2-Piperazine carboxylic acid;1-N-BOC-4-N-Cbz-piperazine-2-carboxylic acid;4-Cbz-1-Boc-Piperazine-2-carboxylic acid
• CAS NO: 149057-19-2
• Molecular Formula: C₁₈H₂₄N₂O₆
• Molecular Weight: 364.39
• Mol File: 149057-19-2.mol

Chemical Properties

• Boiling Point: 518.912 °C at 760 mmHg
• Flash Point: 267.629 °C
• Appearance: /
• Density: 1.272
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.69±0.20(Predicted)
• CAS DataBase Reference: N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID(149057-19-2)
• EPA Substance Registry System: N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID(149057-19-2)

Safety Data

• Hazardous Substances Data: 149057-19-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID is used as a key intermediate for the synthesis of N-aryl piperazines. These N-aryl piperazines are being explored as potential CXCR4 antagonists and antivirals, which can have significant implications in the treatment of various diseases and conditions. The compound's unique structure allows for the development of new drugs with improved efficacy, selectivity, and reduced side effects.
Used in Antiviral Applications:
N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID is used as a precursor in the development of new antiviral agents. The synthesized N-aryl piperazines can potentially inhibit viral replication and entry into host cells, providing a novel approach to combat viral infections. This application is particularly relevant in the context of emerging and re-emerging viral diseases, where there is an ongoing need for new and effective antiviral therapies.
Used in Cancer Research:
In addition to its role in antiviral drug development, N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID is also utilized in the synthesis of compounds with potential applications in cancer research. The resulting N-aryl piperazines may exhibit anti-cancer properties by targeting specific cellular pathways and receptors, thereby contributing to the development of novel cancer therapeutics.
Used in Drug Delivery Systems:
N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID can be employed in the design and development of drug delivery systems, particularly for the targeted delivery of CXCR4 antagonists and antivirals. By incorporating N-1-BOC-N-4-CBZ-2-PIPERAZINE CARBOXYLIC ACID into the design of drug carriers, researchers can potentially improve the bioavailability, stability, and targeted delivery of these therapeutic agents, leading to enhanced treatment outcomes and reduced side effects.

Upstream product

• 1214196-85-6 1-(tert-butoxycarbonyl)piperazine-2-carboxylic acid 
• 501-53-1 benzyl chloroformate 
• 1279816-75-9 C₂₀H₂₈N₂O₆ 
• 2762-32-5 piperazine-2-carboxylic acid 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 24424-99-5 di-tert-butyl dicarbonate 
• 934630-06-5 4-(benzyloxy-carbonyl)-2-piperazinecarboxylic acid 
• 129799-14-0 4-benzyl 1-(tert-butyl) 2-methyl piperazine-1,2,4-tricarboxylate 

Downstream Products

• 1259014-00-0 4-benzyl 1-tert-butyl 2-(methylcarbamoyl)piperazine-1,4-dicarboxylate 
• 1311151-00-4 C₂₉H₃₀F₃N₃O₆S 
• 1311151-19-5 C₂₇H₂₆F₃N₃O₆S 
• 1311151-21-9 C₂₇H₃₂F₃N₃O₆S 
• 1311151-23-1 C₂₇H₂₅F₄N₃O₆S 
• 1311151-25-3 C₂₈H₂₈F₃N₃O₆S 
• 1311151-27-5 C₂₈H₂₅F₆N₃O₇S 
• 1311151-30-0 C₂₈H₂₅F₆N₃O₆S 
• 1311151-34-4 C₂₈H₂₅F₆N₃O₇S 
• 1311151-36-6 C₂₈H₂₅F₆N₃O₆S 
• 1311151-38-8 C₃₃H₃₀F₃N₃O₆S 
• 1311151-40-2 C₂₈H₂₈F₃N₃O₇S 
• 1311151-42-4 C₂₇H₂₅F₄N₃O₆S 
• 1311151-44-6 C₂₉H₃₀F₃N₃O₈S 

Relevant articles and documents

SMALL MOLECULES THAT SENSITIZE HIV-1 INFECTED CELLS TO ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY

Compounds and methods of treating HIV-1 in a human infected with HIV-1 or preventing HIV-1 infection in a human susceptible to infection with HIV-1 are provided. The compounds are of formula (I), (II), and (IA), wherein R1-R7, X, X', Y, Y', Z, and n are defined herein, and the methods comprises administering therapeutically effective amounts of these compounds to the human.

HEPATITIS B CAPSID ASSEMBLY MODULATORS

Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.

SAR studies on a series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl) piperazine-2-carboxamides: Potent inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus

Described herein is the initial optimization of (+/-) N-benzyl-4- heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamide (1), a hit discovered in a high throughput screen run against the NS5B polymerase enzyme of the hepatitis C virus. This effort resulted in the identification of (S)-N-sec-butyl-6-((R)-3- (4-(trifluoromethoxy)benzylcarbamoyl)-4-(4-(trifluoromethoxy)phenylsulfonyl) piperazin-1-yl)pyridazine-3-carboxamide (2), that displayed potent replicon activities against HCV genotypes 1b and 1a (EC50 1b/1a = 7/89 nM).

OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE

Compounds and compositions of said compounds along with methods of use of compounds are disclosed for treating ophthalmic conditions related to mislocalization of opsin proteins, the misfolding of mutant opsin proteins and the production of toxic visual cycle products that accumulate in the eye. Compounds and compositions useful in the these methods, either alone or in combination with other therapeutic agents, are also described.

NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE

The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives that possess unique antiviral activity are provided. These compounds are useful the treatment of HIV and AIDS.

Substituted β-alanine derivatives as cell adhesion inhibitors

β-Alanine derivatives of Formula I are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.

Efflux pump inhibitors

Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.